Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
NCT03241940Phase 1Active, not recruiting
- Sponsor
- Stanford University
- Start
- Oct 2017
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22-CAR T cells in acute lymphoblastic leukemia (ALL) and B cell lymphoma, sponsored by Stanford University. Primary endpoints: Incidence and severity of dose limiting toxicities up to 28 days and Rate of successful manufacture and expansion of the CD19/CD22 CAR T cells. Started Oct 2017; status: active, not recruiting.
02
Drugs
CD19/CD22-CAR T cells
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT03241940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241940.